Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration
NCT05584631Phase 1Recruiting
- Sponsor
- Rutgers University
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of IgPro10 in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by Rutgers University. Primary endpoints: Assessment of drug half-life at 4 weeks, Assessment of immune globulin G serum concentration after intravenous immune globulin G administration at 14 days and 1 more. Started Sep 2022; status: recruiting.
02
Drugs
IgPro10
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT05584631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05584631.